Published on 7 October 2022
Description:
ESMO 2022: changing the future of oncology; the complexities of current generation CAR-T therapies; why community engagement is vital
Categories:
Pharmaceutical Market EuropePreview:
30 articles from this collection:
PME April 2022
2 - PMLIVE
3 - Comment
4 - PMEA
5 - Contents
6-7 - News
6-7 - PME - Pharma Market Europe Pharmaceutical News
8-9 - News
10-11 - Coronavirus news
12 - DARWIN'S MEDICINE - COVID-19’s consequences
12 - Pharma Market Europe Darwin’s medicine
13 - PUBLIC HEALTH AND POLICY - A day late and a dollar short
The technology responses to this pandemic have fallen far short of expectations
14 - MIKE DIXON - About well-being
15 - PHARMA STRATEGIST’S BLOG - The health paradigm shift
16-17 - ESMO 2022 Congress - Putting the ovation into innovation: trends from ESMO
18-19 - CAR-T CELL THERAPY - CAR-T cell therapy in oncology
20-21 - TL HANOVER - Despite the rise of digital technology in clinical trials, community engagement has never been so important
22-23 - TL LANGLAND- Who needs to be trusted anyway?
24-25 - VALUE-BASED HEALTHCARE - The importance of value when treating patients
26-27 - RARE DISEASE - Rare disease drug development – real-world evidence innovations with historical controls
28 - EBR
29 - OCTOBER Highlights
30-31 - Antimicrobial resistance - Creating the urgency and drive needed to tackle antimicrobial resistance
32 - TL ASHFIELD - Antimicrobial resistance – the silent pandemic
33 - TL NZYME - Reimbursement ≠ patient access
34-35 - MARKET ACCESS - Are smart deals a clever solution to UK market access?
36-37 - FUNCTIONAL SKILLS - Cross-functional alignment
38-40 - Appointments
41 - HEALTHCARE COMMS
42 - Q&A - Julia Kirby
43 - Recruitment
43 - Pharma Market Europe (PME) Recruitment
44 - NUCLEUS GLOBAL
Pharmaceutical Market Europe (PME)
Pharmaceutical industry news, articles, jobs, reports, advice and services